<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536415</url>
  </required_header>
  <id_info>
    <org_study_id>20-VIN-0051</org_study_id>
    <nct_id>NCT04536415</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers</brief_title>
  <official_title>Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Oseltamivir Phosphate 75 mg Capsule of Yangtze River Pharmaceutical (Group) Co., Ltd., China and TAMIFLU® (Oseltamivir Phosphate) Capsules 75 mg of Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 in Healthy, Adult, Human Subjects Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austarpharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austarpharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the bioequivalence of Oseltamivir Phosphate Capsules 75 mg versus&#xD;
      TAMIFLU 75 mg capsules administered as 75 mg capsules in healthy volunteers under Fed&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">August 27, 2020</completion_date>
  <primary_completion_date type="Actual">August 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Drug Concentration in Plasma After Single Dose Administration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum measured concentration over the time span specified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</measure>
    <time_frame>48 hours</time_frame>
    <description>The area under the concentration versus time curve, from time 0 to the last measurable concentration, where t = time of last measurable concentration, calculated using linear trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC)</measure>
    <time_frame>48 hours</time_frame>
    <description>The area under the concentration versus time curve from time 0 to infinity AUC0-∞ = AUC0-t + Clast/Kel; where Clast is last measurable concentration, Kel is elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Oseltamivir Phosphate 75 mg capsules (Yangtze River)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamiflu capsules 75 mg (Genentech, Inc.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir Phosphate 75 mg capsules</intervention_name>
    <description>Capsules, 75 mg, single, oral dose</description>
    <arm_group_label>Oseltamivir Phosphate 75 mg capsules (Yangtze River)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamiflu capsules 75 mg</intervention_name>
    <description>Capsules, 75 mg, single, oral dose</description>
    <arm_group_label>Tamiflu capsules 75 mg (Genentech, Inc.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects' weight within normal range according to normal values for Body Mass Index&#xD;
             (18.50 to 30.00 kg/m2) with minimum of 50 kg weight.&#xD;
&#xD;
          -  Subjects with Hemoglobin level ≥ 11.5 G% at the time of screening.&#xD;
&#xD;
          -  Subjects with normal health as determined by personal medical and medication history,&#xD;
             clinical examination and laboratory examinations within the clinically acceptable&#xD;
             normal range.&#xD;
&#xD;
          -  Subjects having clinically acceptable 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          -  Subjects having clinically acceptable chest X-Ray (PA view).&#xD;
&#xD;
          -  Subjects having negative urine screen for drugs of abuse (including amphetamines,&#xD;
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).&#xD;
&#xD;
          -  Subjects having negative alcohol breath test or urine alcohol test.&#xD;
&#xD;
          -  Subjects willing to adhere to the protocol requirements and to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  For Male Subjects: Subjects willing to follow approved birth control methods (a double&#xD;
             barrier method) for the duration of the study as judged by the investigator(s), such&#xD;
             as (a double barrier method) condom with spermicide ,Condom with diaphragm , or&#xD;
             abstinence, subjects should also not donate sperm during this time.&#xD;
&#xD;
          -  Subjects having negative urine pregnancy test at screening and negative Serum β-hCG&#xD;
             pregnancy test on admission day of period 01 (only for female subjects).&#xD;
&#xD;
          -  For Female Subjects: Female of child bearing potential practicing an acceptable method&#xD;
             of birth control for the duration of the study as judged by the investigator(s), such&#xD;
             as intrauterine device (IUD), or abstinence or double barrier contraception, i.e.,&#xD;
             condom + diaphragm, condom + spermicidal or foam; or Postmenopausal for at least 1&#xD;
             year, or if less than 1 year, then following acceptable contraceptive measures as&#xD;
             mentioned above; Surgically sterile (bilateral tubal ligation, bilateral oophorectomy,&#xD;
             or hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to Oseltamivir or related class of drugs or any of its excipients or&#xD;
             to heparin.&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, endocrine, immunological, dermatological, neurological or&#xD;
             psychiatric disease or disorder.&#xD;
&#xD;
          -  Any treatment which could bring about induction or inhibition of hepatic microsomal&#xD;
             enzyme system within 30 days prior to dosing of period 01.&#xD;
&#xD;
          -  Presence of significant alcoholism or drug abuse.&#xD;
&#xD;
          -  History or presence of significant smoking (more than 10 cigarettes or beedis/day).&#xD;
&#xD;
          -  History or presence of asthma, urticaria or other significant allergic reactions.&#xD;
&#xD;
          -  History or presence of significant gastric and/or duodenal ulceration or&#xD;
             gastrointestinal (GI) bleeding.&#xD;
&#xD;
          -  History or presence of significant thyroid disease, adrenal dysfunction, organic&#xD;
             intracranial lesion such as pituitary tumor.&#xD;
&#xD;
          -  History or presence of cancer or basal or squamous cell carcinoma.&#xD;
&#xD;
          -  Difficulty with donating blood.&#xD;
&#xD;
          -  Difficulty in swallowing solids like tablets or capsules.&#xD;
&#xD;
          -  Use of any prescribed medication or OTC medication within 30 days prior to dosing in&#xD;
             period 01.&#xD;
&#xD;
          -  Major illness within past 3 months.&#xD;
&#xD;
          -  Volunteer who have donated blood (1 unit) or participation in a drug research study&#xD;
             within past 90 days prior to the first dose of the study drug.&#xD;
&#xD;
          -  Consumption of xanthine-containing products, tobacco containing products or alcohol&#xD;
             within 48 hours prior to dosing of period 01.&#xD;
&#xD;
          -  Consumption of grapefruit or grapefruit juice containing products within 72 hours&#xD;
             prior to dosing of period 01.&#xD;
&#xD;
          -  Positive screening test result for any one or more: HIV, Hepatitis B and Hepatitis C.&#xD;
&#xD;
          -  History or presence of significant easy bruising or bleeding.&#xD;
&#xD;
          -  History or presence of significant recent trauma.&#xD;
&#xD;
          -  Subjects who have been on an abnormal diet (for whatever reason) during the four weeks&#xD;
             preceding the study.&#xD;
&#xD;
          -  Female subjects who are currently breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas Talati, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doris Zhang</last_name>
    <phone>732331-7315</phone>
    <email>doris.zhang@austarpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Austarpharma Llc</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Zhang</last_name>
      <phone>732-331-7315</phone>
      <email>doris.zhang@austarpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

